Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exelixis, Inc.
< Previous
1
2
3
4
Next >
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
September 12, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
August 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
August 23, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
August 21, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
July 23, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
July 18, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
May 30, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
May 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
May 03, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
May 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 25, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Advances Board Refreshment Plan
April 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Reiterates Commitment to Shareholder Value Creation
April 05, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces $550 Million Share Repurchase Program
March 20, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
March 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
March 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 28, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
February 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
January 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Update on Patent Litigation with MSN Laboratories
January 19, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
January 08, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
January 03, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
December 22, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
November 30, 2022
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.